Skip to main content

FDA Approvals

FDA Approvals, News & Updates - August 2018

Oncology Drugs Approved by the FDA in Early 2018

A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath

Gillian Woollett, MA, DPhil , Bruce S. Pyenson, FSA, MAAA

FDA Approvals, Payers' Guide

Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals

FDA Approvals, Introduction, Payers' Guide

FDA Approvals in 2017 Represent a 21-Year High

Gary M. Owens, MD

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2017

Payers' Guide, FDA Approvals

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Payers' Guide, FDA Approvals

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis

Lisa A. Raedler, PhD, RPh

Page 27 of 53
Results 261 - 270 of 527